Why IsoRay (ISR) Stock Is Surging Today

NEW YORK (TheStreet) -- IsoRay  (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.

IsoRay reported the treatment of a brain tumor that had metastasized from esophageal cancer with the company's liquid Cesium-131, also called Cesitrex, which recently received FDA clearance for internal radiation therapy. The treatment used GliaSite radiation therapy Balloon Catheter System, which delivers a high dose of radiation to an area and minimizes radiation exposure to healthy brain tissue.

The stock was up 10.12% to $2.94 at 10:36 a.m. on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ISR Chart

ISR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Insider Trading Alert - STRP, ISR And TCRD Traded By Insiders

Insider Trading Alert - ISR, AAT And FB Traded By Insiders

Insider Trading Alert - ISR, SIX And SUMR Traded By Insiders

Strong On High Volume: IsoRay (ISR)

Trade-Ideas: IsoRay (ISR) Is Today's "Dead Cat Bounce" Stock